We recently contacted all stakeholders for the appraisal of pembrolizumab for adjuvant treatment of renal cell carcinoma regarding a delay to this topic for operational reasons.
Pembrolizumab for adjuvant treatment of renal cell carcinoma has now been rescheduled into the work programme. The appraisal is due to start early September 2021 and will be discussed at committee in mid-May 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.